| 2025 | 2024 | 2023 | 2022 | |||||
|---|---|---|---|---|---|---|---|---|
| Gross margin | 79,5 k € | +192.7% | -85,7 k € | -158.8% | 145,9 k € | +250.2% | -97,1 k € | |
| EBITDA | 28,5 k € | +120.0% | -142,6 k € | -230.1% | 109,6 k € | +212.4% | -97,5 k € | |
| Operating profit | -131,2 k € | +59.4% | -323,2 k € | -99.7% | -161,8 k € | +12.4% | -184,8 k € | |
| Profit/loss | -138,3 k € | +56.6% | -318,7 k € | -103.2% | -156,8 k € | +13.8% | -181,9 k € | |
| Equity | -102,4 k € | +60.8% | -260,8 k € | -551.1% | 57,8 k € | +133.2% | -174,4 k € | |
| Total assets | 102,3 k € | +14.0% | 89,8 k € | -67.6% | 277,2 k € | +449.4% | 50,4 k € | |
| Cash | 22,6 k € | +178.6% | 8,1 k € | -96.0% | 204,8 k € | +701.1% | 25,6 k € | |
| Debts | 204,1 k € | -41.6% | 349,4 k € | +59.3% | 219,3 k € | -2.4% | 224,8 k € | |
Private limited company · Tongeren-Borgloon · incorporated on 04/01/2022
Private limited company loss-making in the latest fiscal year. Cash position rising (+178.6%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Impact Omics is a Private limited company incorporated in 2022. Its main activity is: Other human health activities. Its registered office is in Tongeren-Borgloon.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette